Standout Papers

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV 2019 2026 2021 2023 425
  1. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV (2019)
    François Venter, Michelle Moorhouse et al. New England Journal of Medicine
  2. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial (2024)
    Cissy Kityo, Ivan Mambule et al. The Lancet Infectious Diseases

Immediate Impact

1 from Science/Nature 14 standout
Sub-graph 1 of 6

Citing Papers

Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection
2024 Standout
2 intermediate papers

Works of Simiso Sokhela being referenced

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
2019 Standout

Author Peers

Author Last Decade Papers Cites
Simiso Sokhela 586 314 464 30 748
Godspower Akpomiemie 633 328 410 24 849
Megan Turner 616 297 503 39 870
Celicia Serenata 633 343 362 18 793
Jessica L. Castilho 479 210 354 38 726
Allison Ross Eckard 390 250 600 46 924
Corrilynn O. Hileman 385 356 682 47 981
Wisit Prasithsirikul 698 323 233 52 955
Kunjal Patel 461 184 425 44 711
Nikolas Wada 524 362 416 17 954
Aoife G. Cotter 437 205 405 42 798

All Works

Loading papers...

Rankless by CCL
2026